References
- Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci. 2015 Jul;36(7):422–439. PubMed PMID: 25975227
- Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. Pharmacol Res. 2020 Feb;152:104609. PubMed PMID: 31862477.
- Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacol Res. 2019 Jun;144:19–50. PubMed PMID: 30877063.
- Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update. Pharmacol Res. 2021 Mar;165:105463. PubMed PMID: 33513356.
- U.S. Food and Drug Administration. XALKORI® (crizotinib) capsules, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202570s030lbl.pdf [Accessed 18 March 2021].
- U.S. Food and Drug Administration. ZYKADIA® (ceritinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf [Accessed 18 March 2021].
- U.S. Food and Drug Administration. ALECENSA® (alectinib) capsules, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s010lbl.pdf [Accessed 18 March 2021].
- U.S. Food and Drug Administration. ALUNBRIG® (brigatinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208772s008lbl.pdf [Accessed 18 March 2021].
- U.S. Food and Drug Administration. LORBRENA® (lorlatinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf [Accessed 18 March 2021].
- U.S. Food and Drug Administration. ROZLYTREK (entrectinib) capsules, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf [Accessed 18 March 2021].
- Yang S, Wu L, Li X, et al. Crizotinib-associated toxic epidermal necrolysis in an ALK-positive advanced NSCLC patient. Mol Clin Oncol. 2018 Mar;8(3):457–459. PubMed PMID: 29456853.
- Gleue CA, Shah K, Wentworth A, et al. Cutaneous sarcoid-like drug reaction caused by an anaplastic lymphoma kinase inhibitor. J Cutan Pathol. 2021 Mar;48(3):425–428. PubMed PMID: 33128468.
- Rossari F, Minutolo F, Orciuolo E. Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J Hematol Oncol. 2018 Jun 20;11(1):84. PubMed PMID: 29925402.
- Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov. 2007 Oct;6(10):834–848. PubMed PMID: 17853901
- Vastarella M, Fabbrocini G, Sibaud V. Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: a Comprehensive Review. Drug Saf. 2020 May;43(5):395–408. PubMed PMID: 31981081
- Macdonald JB, Macdonald B, Golitz LE, et al. Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane. J Am Acad Dermatol. 2015 Feb;72(2):203–218. quiz 219–20 PubMed PMID: 25592338.
- Park SR, Ryu MH, Ryoo BY, et al. Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: management and Clinical Implications. Cancer Res Treat. 2016 Jan;48(1):162–170. PubMed PMID: 26323636.
- Ben Ami E, Demetri GD. A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor. Expert Opin Drug Saf. 2016;15(4):571–578. PubMed PMID: 26865352
- Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol. 2003 Feb;48(2):201–206. PubMed PMID: 12582389.
- Rehman H, Hakim N, Sugarman R, et al. Hyperpigmentation due to imatinib: a rare case of cutaneous involvement. J Oncol Pharm Pract. 2020 Sep;26(6):1511–1515. PubMed PMID: 32067560.
- Mariani S, Abruzzese E, Basciani S, et al. Reversible hair depigmentation in a patient treated with imatinib. Leuk Res. 2011 Jun;35(6):e64–6. PubMed PMID: 21176848.
- Kuraishi N, Nagai Y, Hasegawa M, et al. Lichenoid Drug Eruption with Palmoplantar Hyperkeratosis due to Imatinib Mesylate: a Case Report and a Review of the Literature. Acta Derm-Venereol. PubMed PMID: 20107730. 2010;90 1:73–76.
- Cho AY, Kim DH, Im M, et al. Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec). Ann Dermatol. 2011 Dec;23(3):S360–3. PubMed PMID: 22346278.
- Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol. 2006 Mar;5(3):228–231. PubMed PMID: 16573254.
- Schwarz M, Kreuzer KA, Baskaynak G, et al. Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol. 2002 Oct;69(4):254–256. PubMed PMID: 12431246.
- Rousselot P, Larghero J, Raffoux E, et al. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate. Br J Haematol. 2003 Mar;120(6):1091–1092. PubMed PMID: 12648085.
- Garcia-Romero MT, Duran-mckinster C, de Ocariz MS, et al. Imatinib mesylate-induced neutrophilic folliculitis in a teenager. Int J Dermatol. 2012 Dec;51(12):1529–1530. PubMed PMID: 22486540.
- Mathew T, Chandrashekar L, Pulimood S, et al. Imatinib-induced erythroderma. Australas J Dermatol. 2007 Aug;48(3):193–194. PubMed PMID: 17680975.
- U.S. Food and Drug Administration. GLEEVEC® (imatinib mesylate) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf[Accessed 18 March 2021].
- Inayat F, Saif MW. New Drug and Possible New Toxicity - Squamous Cell Carcinoma Following Imatinib in Patients with Gastrointestinal Stromal Tumors. Anticancer Res. 2016 Nov;36(11):6201–6204. PubMed PMID: 27793952
- Fujii M, Iwasaki T, Takahashi I, et al. Squamous cell carcinoma in a chronic myelogenous leukemia patient treated with imatinib mesylate. J Dermatol. 2015 Mar;42(3):338–339. PubMed PMID: 25580575.
- Ransohoff JD, Kwong BY. Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies. Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):834–851. PubMed PMID: 28918995.
- Drucker AM, Wu S, Busam KJ, et al. Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization. Eur J Haematol. 2013 Feb;90(2):142–150. PubMed PMID: 23240881.
- Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006 Oct 6;6(10):803–812. PubMed PMID: 16990857.
- U.S. Food and Drug Administration. TASIGNA® (nilotinib) capsules, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022068s033lbl.pdf [Accessed 18 March 2021].
- U.S. Food and Drug Administration. SPRYCEL (dasatinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf [Accessed 18 March 2021].
- Shen AQ, Wilson NM, Gleason SL, et al. Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview. Ther Adv Hematol. 2014 Feb 5;5(1):13–17. PubMed PMID: 24490020.
- U.S. Food and Drug Administration. BOSULIF® (bosutinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203441s018lbl.pdf [Accessed 18 March 2021].
- Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011 Oct 27;118(17):4567–4576. PubMed PMID: 21865346.
- Teigen IA, Saele AKM, Reikvam H. A patient with maculopapular rash and lichenoid skin damage caused by ponatinib. J Int Med Res. 2020 Apr;48(4):300060520903660. PubMed PMID: 32242465
- Lipton JH, Chuah C, Guerci-Bresler A, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016 May;17(5):612–621. PubMed PMID: 27083332.
- Jack A, Mauro MJ, Ehst BD. Pityriasis rubra pilaris-like eruption associated with the multikinase inhibitor ponatinib. J Am Acad Dermatol. 2013 Nov;69(5):e249–e250. PubMed PMID: 24124847
- Thakur V, Malhotra P, Lad D, et al. Ponatinib-induced lamellar ichthyosis-like eruption. Int J Dermatol. 2020 May;59(5):e156–e157. PubMed PMID: 32196645.
- U.S. Food and Drug Administration. ZELBORAF® (vemurafenib) tablet, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf [Accessed 18 March 2021].
- Peuvrel L, Quereux G, Saint-Jean M, et al. Profile of vemurafenib-induced severe skin toxicities. J Eur Acad Dermatol Venereol. 2016 Feb;30(2):250–257. PubMed PMID: 26524690.
- U.S. Food and Drug Administration. TAFINLAR® (dabrafenib) capsules, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf [Accessed 18 March 2021].
- U.S. Food and Drug Administration. BRAFTOVI® (encorafenib) capsules, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf [Accessed 18 March 2021].
- U.S. Food and Drug Administration. IMBRUVICA® (ibrutinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205552s033,210563s010lbl.pdf [Accessed 18 March 2021].
- U.S. Food and Drug Administration. CALQUENCE® (acalabrutinib) capsules, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210259s006s007lbl.pdf [Accessed 18 March 2021].
- U.S. Food and Drug Administration. BRUKINSA™ (zanubrutinib) capsules, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf [Accessed 18 March 2021].
- Sibaud V, Beylot-Barry M, Protin C, et al. Dermatological Toxicities of Bruton’s Tyrosine Kinase Inhibitors. Am J Clin Dermatol. 2020 Dec;21(6):799–812. PubMed PMID: 32613545.
- Mariano M, Donati P, Cameli N, et al. Ribociclib-Induced Erythema Dyschromicum Perstans (Ashy Dermatosis)-Like Pigmentation in a Metastatic Breast Cancer Patient. J Breast Cancer. 2021 Feb;24(1):117–121. PubMed PMID: 33634626.
- Ippolito E, Greco C, Silipigni S, et al. Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: preliminary assessment of toxicity. Breast. 2019 Aug;46:70–74. PubMed PMID: 31100573.
- Lasheen S, Shohdy KS, Kassem L, et al. Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. Expert Rev Anticanc. PubMed PMID: 28699811. 2017;179:851–856.
- U.S. Food and Drug Administration. KISQALI ® (ribociclib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209092s005lbl.pdf [Accessed 18 March 2021].
- U.S. Food and Drug Administration. VERZENIO® (abemaciclib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208716s004lbl.pdf [Accessed 18 March 2021].
- U.S. Food and Drug Administration. IBRANCE® (palbociclib) capsules, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207103Orig1s012lbl.pdf [Accessed 18 March 2021].
- Lopez-Gomez V, Yarza R, Munoz-Gonzalez H, et al. Ribociclib-Related Stevens-Johnson Syndrome: oncologic Awareness, Case Report, and Literature Review. J Breast Cancer. 2019 Dec;22(4):661–666. PubMed PMID: 31897340.
- Annunziata MC, Ferrillo M, Cinelli E, et al. Retrospective Analysis of Skin Toxicity in Patients under Anti-EGFR Tyrosine Kinase Inhibitors: our Experience in Lung Cancer. Open Access Maced J Med Sci. 2019 Mar 30;7(6):973–977. PubMed PMID: 30976343.
- Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration Drug Approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res. 2004 Feb 15;10(4):1212–1218. PubMed PMID: 14977817.
- U.S. Food and Drug Administration. IRESSA (gefitinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206995s003lbl.pdf [Accessed 18 March 2021].
- Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010 Feb;11(2):121–128. PubMed PMID: 20022809.
- Abdelgalil AA, Al-Kahtani HM, Al-Jenoobi FI. Erlotinib. Profiles Drug Subst Excip Relat Methodol. 2020;45:93–117. PubMed PMID: 32164971
- U.S. Food and Drug Administration. TARCEVA (erlotinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf [Accessed 18 March 2021].
- Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther. 2008 Aug;30(8):1426–1447. PubMed PMID: 18803986
- U.S. Food and Drug Administration. TYKERB® (lapatinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf [Accessed 18 March 2021].
- Lacouture ME, Laabs SM, Koehler M, et al. Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat. 2009 Apr;114(3):485–493. PubMed PMID: 18600445.
- Wecker H, Waller CF. Afatinib. Recent Results Cancer Res. 2018;211:199–215. PubMed PMID: 30069769
- Barron F, de La Torre-vallejo M, Luna-Palencia RL, et al. The safety of Afatinib for the treatment of non-small cell lung cancer. Expert Opin Drug Saf. 2016 Nov;15(11):1563–1572. PubMed PMID: 27633264.
- U.S. Food and Drug Administration. GILOTRIF® (Afatinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf [Accessed 18 March 2021].
- Tang ZH, Lu JJ. Osimertinib resistance in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Lett. 2018 Apr 28;420:242–246. PubMed PMID: 29425688.
- U.S. Food and Drug Administration. TAGRISSO® (osimertinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf [Accessed 18 March 2021].
- Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016 Mar;17(3):367–377. PubMed PMID: 26874901.
- U.S. Food and Drug Administration. NERLYNX® (neratinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208051s007lbl.pdf [Accessed 18 March 2021].
- Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1454–1466. PubMed PMID: 28958502.
- Lavacchi D, Mazzoni F, Giaccone G. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives. Drug Des Devel Ther. 2019;13:3187–3198. PubMed PMID: 31564835
- Mok TS, Cheng Y, Zhou X. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR -Activating Mutations. J Clin Oncol. 2018 Aug 1;36(22):2244–2250. PubMed PMID: 29864379.
- U.S. Food and Drug Administration. VIZIMPRO® (dacomitinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211288s003lbl.pdf [Accessed 18 March 2021].
- U.S. Food and Drug Administration. JAKAFI® (ruxolitinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202192Orig1s019Rpllbl.pdf [Accessed 10 April 2021].
- U.S. Food and Drug Administration. XELJANZ® (tofacitinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203214s026lbl.pdf [Accessed 10 April 2021].
- U.S. Food and Drug Administration. OLUMIANT (baricitinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/207924s002lbl.pdf [Accessed 10 April 2021].
- U.S. Food and Drug Administration. INREBIC® (fedratinib) capsules, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf [Accessed 10 April 2021].
- U.S. Food and Drug Administration. RINVOQ™ (upadacitinib) extended-release tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211675s001lbl.pdf [Accessed 10 April 2021].
- Macdonald JB, Macdonald B, Golitz LE, et al. Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol. 2015 Feb;72(2):221–36;quiz 237–8. PubMed PMID: 25592339.
- Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012 Jul 12;367(2):107–114. PubMed PMID: 22663011.
- U.S. Food and Drug Administration. MEKINIST® (trametinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204114s016lbl.pdf [Accessed 18 March 2021].
- U.S. Food and Drug Administration. COTELLIC® (cobimetinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206192s002lbl.pdf [Accessed 18 March 2021].
- U.S. Food and Drug Administration. MEKTOVI® (binimetinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210498s001lbl.pdf [Accessed 18 March 2021].
- U.S. Food and Drug Administration. KOSELUGO (selumetinib) capsules, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf [Accessed 18 March 2021].
- Campagne O, Yeo KK, Fangusaro J, et al. Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib. Clin Pharmacokinet. 2020 Dec 23;60(3):283–303. PubMed PMID: 33354735.
- Greenwell IB, Ip A, Cohen JB. PI3K Inhibitors: understanding Toxicity Mechanisms and Management. Oncology (Williston Park). 2017 Nov15;31(11):821–828. PubMed PMID: 29179250.
- U.S. Food and Drug Administration. ZYDELIG® (idelalisib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205858s014lbl.pdf [Accessed 18 March 2021].
- Massey PR, Okman JS, Wilkerson J, et al. Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature. Support Care Cancer. 2015 Jun;23(6):1827–1835. PubMed PMID: 25471178.
- U.S. Food and Drug Administration. NEXAVAR (sorafenib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021923s024lblrpl.pdf [Accessed 18 March 2021].
- U.S. Food and Drug Administration. SUTENT® (sunitinib malate) capsules, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021938s037lbl.pdf [Accessed 18 March 2021].
- U.S. Food and Drug Administration. VOTRIENT® (pazopanib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022465s029lbl.pdf [Accessed 18 March 2021].
- U.S. Food and Drug Administration. CABOMETYX® (cabozantinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208692s010lbl.pdf [Accessed 18 March 2021].
- Bennani-Lahlou M, Mateus C, Escudier B, et al. [Eruptive nevi associated with sorafenib treatment]. Ann Dermatol Venereol. 2008 Oct;135(10):672–674. PubMed PMID: 18929917.
- Kong HH, Sibaud V, Chanco Turner ML, et al. Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol. 2008 Jun;144(6):820–822. PubMed PMID: 18559790.
- Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol. 2009 Aug 10;27(23):e59–61. PubMed PMID: 19597016.
- Guevremont C, Alasker A, Karakiewicz PI. Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma. Curr Opin Support Palliat Care. 2009 Sep 3;3(3):170–179. PubMed PMID: 19528803.
- Akanay-Diesel S, Hoff NP, Kurle S, et al. Sunitinib induced pyoderma gangrenosum-like ulcerations. European Journal of Medical Research. 2011 Nov10;16(11):491–494. PubMed PMID: 22027642.
- Jimenez-Gallo D, Albarran-Planelles C, Linares-Barrios M, et al. Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib. JAMA Dermatol. 2013 May;149(5):624–626. PubMed PMID: 23677103.
- Alpuim Costa D, Baptista de Almeida S, Coelho Barata P, et al. Pazopanib-Induced Cutaneous Leukocytoclastic Vasculitis: an Exclusion Diagnosis of a Multidisciplinary Approach. Case Rep Oncol. 2017 Sep-Dec;10(3):1041–1049. PubMed PMID: 29387004.
- U.S. Food and Drug Administration. CAPRELSA® (vandetanib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022405s017lbl.pdf [Accessed 18 March 2021].
- Giacchero D, Ramacciotti C, Arnault JP, et al. A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol. 2012 Dec;148(12):1418–1420. PubMed PMID: 23247489.
- U.S. Food and Drug Administration. INLYTA® (axitinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202324s011lbl.pdf [Accessed 18 March 2021].
- McLellan B, Ciardiello F, Lacouture ME, et al. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol. 2015 Oct;26(10):2017–2026. PubMed PMID: 26034039.
- U.S. Food and Drug Administration. STIVARGA® (regorafenib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085Orig1s014lbl.pdf [Accessed 18 March 2021].
- Zuo RC, Apolo AB, DiGiovanna JJ, et al. Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib. JAMA Dermatol. 2015 Feb;151(2):170–177. PubMed PMID: 25427282.
- U.S. Food and Drug Administration. OFEV® (nintedanib) capsules, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205832s014lbl.pdf [Accessed 18 March 2021].
- U.S. Food and Drug Administration. LENVIMA® (lenvatinib) capsules, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206947s018lbl.pdf [Accessed 18 March 2021].
- Kim ES. Midostaurin: first Global Approval. Drugs. 2017 Jul;77(11):1251–1259. PubMed PMID: 28612232
- Markham A. Fostamatinib: first Global Approval. Drugs 2018 Jun;78(9):959–963. PubMed PMID: 29869203
- Tarver TC, Hill JE, Rahmat L, et al. Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations. Blood Adv. 2020 Feb 11;4(3):514–524. PubMed PMID: 32040554.
- Kim M, Williams S. Midostaurin in combination with standard chemotherapy for treatment of newly diagnosed fms-like tyrosine kinase 3 (FLT3) mutation-positive acute myeloid Leukemia. Ann Pharmacother. 2018 Apr;52(4):364–369. PubMed PMID: 29231051
- Paudel A, Dhital R, Areoye G, et al. Sweet’s syndrome in a granulocytopenic patient with acute myeloid leukemia on FLT3 inhibitor. J Community Hosp Intern Med Perspect. 2020 Jun 14;10(3):275–278. PubMed PMID: 32850078.
- U.S. Food and Drug Administration. RYDAPT® (midostaurin) capsules, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/207997s006lbl.pdf [Accessed 18 March 2021].
- U.S. Food and Drug Administration. TAVALISSE™ (fostamatinib disodium hexahydrate) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209299lbl.pdf [Accessed 18 March 2021].
- U.S. Food and Drug Administration. XOSPATA® (gilteritinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211349s001lbl.pdf [Accessed 18 March 2021].
- Hanna KS. Erdafitinib to treat urothelial carcinoma. Drugs Today (Barc). 2019 Aug;55(8):495–501. PubMed PMID: 31461086
- Roubal K, Myint ZW, Kolesar JM. Erdafitinib: a novel therapy for FGFR-mutated urothelial cancer. Am J Health Syst Pharm. 2020 Feb 19;77(5):346–351. PubMed PMID: 32073123.
- Loriot Y, Necchi A, Park SH, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019 Jul 25;381(4):338–348. PubMed PMID: 31340094.
- U.S. Food and Drug Administration. BALVERSA (erdafitinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212018s001lbl.pdf [Accessed 18 March 2021].
- Boal LH, Glod J, Spencer M, et al. Pediatric PK/PD phase i trial of pexidartinib in relapsed and refractory leukemias and solid tumors including neurofibromatosis type i-related plexiform neurofibromas. Clin Cancer Res. 2020 Dec 1;26(23):6112–6121. PubMed PMID: 32943455.
- Lamb YN. Pexidartinib: first Approval. Drugs. 2019 Nov;79(16):1805–1812. PubMed PMID: 31602563
- Tap WD, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019 Aug 10;394(10197):478–487. PubMed PMID: 31229240.
- Dhillon S. Avapritinib: first Approval. Drugs. 2020 Mar;80(4):433–439. PubMed PMID: 32100250
- Von Mehren M, Heinrich MC, Shi H, et al. Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data. BMC Cancer. 2021 Mar 19;21(1):291. PubMed PMID: 33740926.
- U.S. Food and Drug Administration. AYVAKIT (avapritinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf [Accessed 30 March 2021].
- U.S. Food and Drug Administration. TUKYSATM (tucatinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf [Accessed 18 March 2021].
- Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020 Feb 13;382(7):597–609. PubMed PMID: 31825569.
- Janku F, Abdul Razak AR, Chi P, et al. Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor: a phase i study of ripretinib. J Clin Oncol. 2020 Oct 1;38(28):3294–3303. PubMed PMID: 32804590.
- Martin-Broto J, Moura DS. New drugs in gastrointestinal stromal tumors. Curr Opin Oncol. 2020 Jul;32(4):314–320. PubMed PMID: 32541319
- Blay JY, Serrano C, Heinrich MC, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Jul;21(7):923–934. PubMed PMID: 32511981.
- U.S. Food and Drug Administration. QINLOCK™ (ripretinib) tablets, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf [Accessed 30 March 2021].
- Hoy SM. Pemigatinib: first Approval. Drugs. 2020 Jun;80(9):923–929. PubMed PMID: 32472305
- Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020 May;21(5):671–684. PubMed PMID: 32203698.
- Markham A. Selpercatinib: first Approval. Drugs. 2020 Jul;80(11):1119–1124. PubMed PMID: 32557397
- U.S. Food and Drug Administration. RETEVMO™ (selpercatinib) capsules, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213246s002lbl.pdf [Accessed 30 March 2021].
- Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol. 2009 Apr 4;4(2):107–119. PubMed PMID: 19452131.
- Tsuchiya N, Narita S, Inoue T, et al. Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma. Anticancer Drugs. 2013 Mar;24(3):310–314. PubMed PMID: 23237922.
- Nakahara T, Moroi Y, Takayama K, et al. Analysis of sebum lipid composition and the development of acneiform rash before and after administration of egfr inhibitor. Curr Oncol. 2015 Apr;22(2):e124–7. PubMed PMID: 25908917.
- Guttman-Yassky E, Mita A, De Jonge M, et al. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur J Cancer. 2010 Jul;46(11):2010–2019. PubMed PMID: 20621734.
- Eaby-Sandy B, Lynch K. Side effects of targeted therapies: rash. Semin Oncol Nurs. 2014 Aug;30(3):147–154. PubMed PMID: 25085026
- Ai L, Xu Z, Yang B, et al. Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management. Expert Rev Clin Pharmacol. 2019 Dec;12(12):1121–1127. PubMed PMID: 31679411.
- Lountzis NI, Maroon MS. Sorafenib-induced palmoplantar hyperkeratosis. J Drugs Dermatol. 2008 Jun;7(6):588–589. PubMed PMID: 18561593
- Yamamoto K, Uda A, Mukai A, et al. Everolimus-induced human keratinocytes toxicity is mediated by STAT3 inhibition. J Exp Clin Cancer Res. 2013 Oct 25;32(1):83. PubMed PMID: 24423131.
- Chanprapaph K, Rutnin S, Vachiramon V. Multikinase inhibitor-induced hand–foot skin reaction: a review of clinical presentation, pathogenesis, and management. Am J Clin Dermatol. 2016 Aug;17(4):387–402. PubMed PMID: 27221667
- Luo P, Yan H, Chen X, et al. s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand-foot skin reaction that can be reversed by nicotinamide. Cell Res. 2020 Apr 15;30(9):779–793. PubMed PMID: 32296111.
- Belum VR, Serna-Tamayo C, Wu S, et al. Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis. Clin Exp Dermatol. 2016 Jan;41(1):8–15. PubMed PMID: 26009777.
- Bos WE, Nijsten TE, de Jonge MJ, et al. Topical psoralen plus UV-A therapy for tyrosine kinase inhibitor-induced hand-foot syndrome. Arch Dermatol. 2012 Apr;148(4):546–547. PubMed PMID: 22508887.
- Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006 Jan 1;24(1):25–35. PubMed PMID: 16314617.
- Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 20;27(27):4462–4468. PubMed PMID: 19652060.
- Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 2007 Apr;12(4):426–437. PubMed PMID: 17470685.
- Dranitsaris G, Vincent MD, Yu J, et al. Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib. Ann Oncol. 2012 Aug;23(8):2103–2108. PubMed PMID: 22228446.
- Balagula Y, Wu S, Su X, et al. The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs. 2012 Aug;30(4):1773–1781. PubMed PMID: 21394443.
- Shi Q, Yang X, Ren L, et al. Recent advances in understanding the hepatotoxicity associated with protein kinase inhibitors. Expert Opin Drug Metab Toxicol. 2020 Mar;16(3):217–226. PubMed PMID: 32050817.
- Kozuki T. Skin problems and EGFR-tyrosine kinase inhibitor. Jpn J Clin Oncol. 2016 Apr;46(4):291–298. PubMed PMID: 26826719
- Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res. 2007 Jul 1;13(13):3913–3921. PubMed PMID: 17606725.
- Liu L, Wang E, Li L, et al. As Clinical markers, hand-foot-skin reaction and diarrhea can predict better outcomes for hepatocellular carcinoma patients receiving transarterial chemoembolization plus sorafenib. Can J Gastroenterol Hepatol. 2019;2019:2576349. PubMed PMID: 3181511